Immuno-Resistance and Sequencing Symposium

Thursday, Nov. 11, 2021

7:30 a.m.–6 p.m. EST

Session I: Novel Primary vs. Adaptive Resistance Mechanisms

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:30 a.m.</td>
<td>Introduction</td>
</tr>
<tr>
<td>7:35 a.m.</td>
<td>Anti-PD1 Resistance – Different Flavors</td>
</tr>
<tr>
<td>7:55 a.m.</td>
<td>Dissecting the Complexity of HLA Loss in Cancer</td>
</tr>
<tr>
<td>8:15 a.m.</td>
<td>Dissecting Evolution of Clinical Immunotherapy Resistance</td>
</tr>
<tr>
<td>8:35 a.m.</td>
<td>Immune Checkpoint Therapy: Identification of Resistance Mechanisms</td>
</tr>
<tr>
<td>8:55 a.m.</td>
<td>Session I Panel Discussion</td>
</tr>
<tr>
<td>9:15 a.m.</td>
<td>Break</td>
</tr>
</tbody>
</table>

Moderator: Ira Mellman, PhD – Genentech, Inc.

Panelists: Session I Speakers
- Michael B. Atkins, MD - Georgetown Lombardi Comprehensive Cancer Center

Session II: Myths vs. Knowledge on Clinical Therapeutic Mechanisms – Lessons Learned

Time: 9:30–11:10 a.m.
**Moderator:** Andrew D. Weinberg, PhD – Earle A. Chiles Research Institute, Providence Portland Medical Center

9:30 a.m. **Single Agent Trials, Lessons Learned - OX40 Agonists are Still Alive**
Andrew D. Weinberg, PhD – Earle A. Chiles Research Institute, Providence Portland Medical Center

9:50 a.m. **Role of Tim3 in Myeloid Cells**
Vijay K. Kuchroo, DVM, PhD – Center for Neurologic Diseases, BWH

10:10 a.m. **Anti-PD1 and IDO1 Inhibition: Lessons Learned**
Lance Leopold, MD – Incyte

10:30 a.m. **Primbing the Immune System to Provoke Checkpoints: The Path to Maintaining the Immunotherapy Momentum**
Elizabeth M. Jaffee, MD – Sidney Kimmel Cancer Center, Johns Hopkins University

10:50 a.m. **Session II Panel Discussion**
**Moderator:** Andrew D. Weinberg, PhD – Earle A. Chiles Research Institute, Providence Portland Medical Center

**Panelists:** Session II Speakers

**Session III: Understanding the Biology of Therapeutic Pillars – Targeted Pathways and Future Direction**

**Time:** 11:10 a.m.–2:20 p.m.

**Moderator:** E. John Wherry, PhD - University of Pennsylvania

11:10 a.m. **VISTA Targeting of T cell Quiescence and Myeloid Suppression Overcomes Adaptive Resistance**
J. Louise Lines, PhD – Dartmouth College

11:30 a.m. **Human Costimulatory Bispecific Antibodies in Cancer Immunotherapy**
Dimitros Skokos, PhD – Regeneron Pharmaceuticals, Inc.

11:50 a.m. **Lunch Break**

1:20 p.m. **In Pre-clinical Models Metabolic Manipulations Improve the Efficacy of T cell Immunotherapy of Melanoma**
Hildegund Ertl, MD – The Wistar Institute

1:40 p.m. **Molecular Mechanisms of T cell Exhaustion and Relevance for Immunotherapy of Cancer**
E. John Wherry, PhD – University of Pennsylvania
Session III Panel Discussion
Moderator: E. John Wherry, PhD - University of Pennsylvania
Panelists: Session III Speakers

Session IV: Resistance Reversal Strategies & Sequencing

Time: 2:20–4:20 p.m.
Moderator: Samir N. Khleif, MD – Georgetown University Medical Center

2:20 p.m. Cellular Mechanisms of Cancer Immunity Response and Resistance
Ira Mellman, PhD – Genentech, Inc.

2:40 p.m. T cell Activation and Timing
Benjamin Youngblood, PhD - St. Jude Children's Research Hospital

3 p.m. Mapping Immunosuppressive Cell in the Tumor Microenvironment
Miriam Merad, MD, PhD – Icahn School of Medicine at Mount Sinai

3:20 p.m. Machine Learning for Spatial Multi-omics in Cancer Immunotherapy
Elana Fertig, PhD - Johns Hopkins University

3:40 p.m. Autophagy and Immunometabolism Regulation of CD8+ T cell Antitumor Immunity
Julian J. Lum, PhD – BC Cancer

4 p.m. Session IV Panel Discussion – Rational Combination Design
Moderator: Samir N. Khleif, MD – Georgetown University Medical Center
Panelists: Session IV Speakers

4:20 p.m. Break

Session V: Developmental Process

Time: 4:35–6 p.m. EST
Moderator: Kald Abdallah, MD, PhD - Bristol Myers Squibb

4:35 p.m. Novel Immunotherapy Clinical Trial Design
Osama E. Rahma, MD – AstraZeneca
4:55 p.m.  **Combinations of Agents without Single-agent Activity**  
Kald Abdallah, MD, PhD – *Bristol Myers Squibb*

5:15 p.m.  **Regulatory Considerations for Cancer Immunotherapeutic Development – anti-PD-(L)1 resistance**  
Marc Theoret, MD – *Food and Drug Administration (FDA)*

5:35 p.m.  **Session V Panel Discussion**  
**Moderator:** Kald Abdallah, MD, PhD - *Bristol Myers Squibb*  
**Panelists:** Session V Speakers

5:55 p.m.  **Closing Remarks**  
Samir N. Khleif, MD – *Georgetown University Medical Center*